Jimy PintoMalia SkjefteJulio Alonso-PadillaDaniel Franz Lozano BeltránLilian PintoAina CasellasMery Elena Arteaga TerrazasKaren GalindoRoxana Challapa QuechoverMaría Escobar Caballero2026-03-222026-03-22202310.1371/journal.pntd.0011498https://doi.org/10.1371/journal.pntd.0011498https://andeanlibrary.org/handle/123456789/46334Citaciones: 5The study confirms that follow-up of benznidazole-treated T. cruzi-infected patients should be longer than five years to determine, with current tools, if they are cured. In terms of serological evolution, the single use of a total antigen ELISA might be a more reliable measure and suffice to address infection status, at least in the region of Bolivia where the study was done. Additional work is needed to develop a test-of-cure for an early assessment of drugs´ efficacy with the aim of improving case management protocols.enBenznidazoleSerologyChagas diseaseNifurtimoxTrypanosoma cruziMedicineInternal medicineClinical trialDiseaseObservational studyarticle